NSE: GLAXO | BSE: 500660

Expensive Star

Download real time

3420.00 174.90 (5.39%)

New 52W High today

282.4K NSE+BSE Volume

NSE 04 Jun, 2025 3:40 PM (IST)

57,936.9

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

Search Inside the pdf :

GlaxoSmithKline Pharmaceuticals Ltd.

14 May 2025

3420.00

5.39%

Sluggish growth; margins may have hit a peak

Sell: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSK) Q4FY25 revenue grew at a slower pace of 4.8% due to slowdown in acute therapy market. Improvement in mix led to 340bps YoY expansion in gross margin while cost savings and productivity improvement fuelled 650bps surge in EBITDA margin.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 19.88% in the last 1 Month

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024

3420.00

5.39%

Superior execution and lower RM costs drive earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Glaxo Pharma (GLXO) delivered better-than-expected 1QFY25 performance. The robust growth in key brands, young potential brands.

Number of FII/FPI investors decreased from 347 to 340 in Mar 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024

3420.00

5.39%

On road to recovery

Hold: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSK) Q1FY25 result was ahead of our expectations driven by mixed improvement and curb in overhead cost.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 19.88% in the last 1 Month

GlaxoSmithKline Pharmaceuticals Ltd.

27 Jul 2023

3420.00

5.39%

Launch cost dents margins

Hold: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q1FY24 performance was largely in line with expectations, though EBITDA margin was weaker due to marketing cost of the newly launched Shingrix (herpes zoster vaccine). GSKP’s focus on volume growth forms the crux of its market-approach strategy as pricing pressure forces companies to think differently.

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2023

3420.00

5.39%

Mandated price cuts dampen margins

Hold: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q4FY23 performance was disappointing with margins taking a hit due to unfavourable mix and price cuts on the NLEM portfolio (42% of sales). GSK’s focus on volume growth forms the crux of its market-approach strategy as pricing pressures force it to think differently.

Number of FII/FPI investors decreased from 347 to 340 in Mar 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

17 May 2023

3420.00

5.39%

Downward revision in realization adversely impacts earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd. has gained 35.71% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

16 Mar 2023

3420.00

5.39%

Outlook - A Mixed Bag

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Phar.. has an average target of 2610.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

08 Feb 2023

3420.00

5.39%

Prudent cost controls support margins

Buy: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q3FY23 performance beat our estimates on the profitability front, led by prudent cost controls. Revenues declined 1.7% YoY to Rs8bn (I-Sec: Rs8.8bn) with slowdown in vaccine sales. EBITDA margins saw strong YoY expansion of 430bps (+50bps QoQ) to 28.5%, largely supported by gross margin expansion and lower ‘other expenses’.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 35.71% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

14 Nov 2022

3420.00

5.39%

Controlled costs support margins

Accumulate: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q2FY23 performance beat our estimates on the profitability front, led by prudent cost controls. Revenue (excluding divested brands) declined 1.8% YoY to Rs9.2bn (I-Sec: Rs9.6bn).